Momentum investing is reminder from nepsall about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at

Vapotherm (VAPO)

, which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Vapotherm currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.

You can see the current list of Zacks #1 Rank Stocks here >>>

Set to Beat the Market?

Let's discuss some of the components of the Momentum Style Score for VAPO that show why this medical technology company shows promise as a solid momentum pick.

A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.

For VAPO, shares are up 0.79% over the past week while the Zacks Medical - Products industry is flat over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 19.98% compares favorably with the industry's 7.79% performance as well.

While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Shares of Vapotherm have increased 128.66% over the past quarter, and have gained 17.75% in the last year. On the other hand, the S&P 500 has only moved -13.44% and -1.39%, respectively.

Story continues

Investors should also take note of VAPO's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now, VAPO is averaging 499,777 shares for the last 20 days.

Earnings Outlook

The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with VAPO.

Over the past two months, 1 earnings estimate moved higher compared to 1 lower for the full year. These revisions helped boost VAPO's consensus estimate, increasing from -$2.39 to -$2.32 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been 1 downward revision in the same time period.

Bottom Line

Taking into account all of these elements, it should come as no surprise that VAPO is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Vapotherm on your short list.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.

Click to get this free report

Vapotherm, Inc. (VAPO) : Free Stock Analysis Report

To read this article on Zacks.com click here.

View comments

• ·Daseke Sees Flatbed Softness Continuing Through First Half Of 2020
• ·ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting
• ·Should You Sell in May or Buy 5 Top Coronavirus-Immune Stocks?
• ·Coronavirus fears spark 'panic buying' of toilet paper, water, hand sanitizer. Here's why we all need to calm down
• ·Suzan Craig and Tahi Restore Nature and Make 100 Percent Natural, Genuine Honey
• ·Are Insiders Buying Arena Events Group plc (LON:ARE) Stock?
• ·EPR Properties: 3Q Earnings Snapshot
• ·AP Top Extended Financial Headlines at 9:52 p.m. EST
• ·J.C. Penney announces locations of 154 stores closing across the US
• ·Cheniere seeks U.S. permission to put Oklahoma Midship natgas pipe in service
• ·Natural Gas Price Fundamental Weekly Forecast – Heating Season Begins with Hedge Funds Holding Long Positions
• ·Trump slams Fed's coronavirus response as 'slow,' renews calls for lower interest rates
• ·InvestmentPitch Media Video Discusses Recent eResearch Buy Recommendation on Peak Positioning Technologies, Parent Company of a Group of FinTech Subsidiaries operating in China - Video Available on Investmentpitch.com
• ·TUI Will Cut Budgets, Freeze Hiring to Deal With Coronavirus Spread
• ·Canada energy firms fret as Ottawa labors over promised aid package
• ·'Big shoes to fill': UniCredit shares tumble as CEO Mustier quits